We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+23.37%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
–
Cap. Flow
+$239M
Cap. Flow %
85.54%
Top 10 Hldgs %
59.33%
Holding
170
New
170
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$36.3M
2
KROS icon
Keros Therapeutics
KROS
+$21.6M
3
ROIV icon
Roivant Sciences
ROIV
+$12.2M
4
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$6.94M
5
ABUS icon
Arbutus Biopharma
ABUS
+$6.79M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 68.64%
2 Technology 1.12%
3 Financials 1.12%
4 Materials 0.99%
5 Consumer Staples 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
151
Protara Therapeutics
TARA
$230M
$4.11K ﹤0.01%
+2,194
New +$3.23K
CLNN icon
152
Clene
CLNN
$68.2M
$3.41K ﹤0.01%
+575
New +$5.01K
SLN
153
Silence Therapeutics
SLN
$554M
$3.3K ﹤0.01%
+190
New +$2.13K
ANEB
154
DELISTED
Anebulo Pharmaceuticals
ANEB
$2.94K ﹤0.01%
+1,217
New +$2.86K
EMCGR
155
DELISTED
Embrace Change Acquisition Corp Rights
EMCGR
$2.72K ﹤0.01%
+18,000
New +$2.25K
LEXX icon
156
Lexaria Bioscience
LEXX
$8.82M
$2.03K ﹤0.01%
+108
New +$2.09K
ECDAW
157
DELISTED
ECD Automotive Design Warrant
ECDAW
$1.3K ﹤0.01%
+32,596
New +$994
FLFVR
158
DELISTED
Feutune Light Acquisition Corporation Right
FLFVR
$1.27K ﹤0.01%
+15,000
New +$1.89K
GLSTW
159
DELISTED
Global Star Acquisition, Inc. Warrants
GLSTW
$1.2K ﹤0.01%
+120,000
New +$1.61K
TVTX icon
160
Travere Therapeutics
TVTX
$5.89B
$899 ﹤0.01%
+100
New +$728
CETUR
161
DELISTED
Cetus Capital Acquisition Corp. Right
CETUR
$873 ﹤0.01%
+4,999
New +$1.05K
OAKUW
162
DELISTED
Oak Woods Acquisition Corp Warrant
OAKUW
$780 ﹤0.01%
+30,000
New +$1.01K
AIMAW
163
DELISTED
Aimfinity Investment Corp I Warrant
AIMAW
$675 ﹤0.01%
+18,000
New +$524
NUBIW
164
DELISTED
Nubia Brand International Corp. Warrant
NUBIW
$634 ﹤0.01%
+13,500
New +$892
SBCWW
165
SBC Medical Group Warrants
SBCWW
$2.88M
$558 ﹤0.01%
+19,800
New +$794
FTIIW
166
DELISTED
FutureTech II Acquisition Corp. Warrant
FTIIW
$447 ﹤0.01%
+30,000
New +$1.06K
FORLW
167
DELISTED
Four Leaf Acquisition Corp Warrants
FORLW
$285 ﹤0.01%
+9,487
New +$509
EMCGW
168
DELISTED
Embrace Change Acquisition Corp Warrants
EMCGW
$234 ﹤0.01%
+18,000
New +$279
FLFVW
169
DELISTED
Feutune Light Acquisition Corporation Warrant
FLFVW
$180 ﹤0.01%
+15,000
New +$244
CETUW
170
DELISTED
Cetus Capital Acquisition Corp. Warrant
CETUW
$72 ﹤0.01%
+5,000
New +$106
3 4 5 6
7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for ADAR1 Capital Management, which disclosed 170 positions worth $280M. Its ten largest holdings account for 59% of the portfolio.

Its largest position is Royalty Pharma: 1,321,834 shares worth $37.1M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, followed by Technology and Financials.

  • ADAR1 Capital Management's largest Q4 2023 buy was Royalty Pharma: 1,321,834 shares worth $37.1M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $280M portfolio in Q4 2023.
  • ADAR1 Capital Management disclosed 170 positions in Q4 2023, its first 13F filing on record.

Based on ADAR1 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.